Radiation Injury Drugs Market Share & Growth | Forecast 2031
Radiation Injury Drugs Market Share & Growth | Forecast 2031
Segments - Global Radiation Injury Drugs Market by Exposure (Internal Exposure and External Exposure), Source (Background Radiation and Man-Made Radiation), Diagnosis (Lymphocytes Count, Geiger-Muller Counter, and Blood Test And Dosimeter), Treatment (Treatment For Radiation Sickness, Treatment For Internal Contamination, and Others), Route Of Administration (Oral and Parenteral), Application (Ambulatory Surgery Centers (ASCs), Hospitals, Research Institutes, and Others), and Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA)) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
Upcoming
| Report ID :HC-2723
| 4.5 Rating
| 72 Reviews
| 299 Pages
| Format :
Report Description
Radiation Injury Drugs Market Outlook
The global radiation injury drugs Market was valued at USD 565.6 million in 2020 and is projected to reach USD 747.9 million by 2028, expanding at a CAGR of 3.7% during the forecast period. Radiation injury is responsible for causing damage to tissues, due to the exposure of ionizing radiation. High dose of ionizing radiation causes acute illness through the reduction in the production of blood cells and damages the digestive tract. Sources of ionizing radiation are natural such as radioactive substances or man-made such as X-ray machines, particle accelerators, nuclear reactors, and nuclear weapons. Tissue damage by radiation therapy leads to skin necrosis, dermatitis, and ulcer. Above 70% of patients experience radiodermatitis, which ranges from dry desquamation, faint erythema, moist desquamation, and necrosis, during the course of radiotherapy.
Systemic radiation therapy uses radioactive drugs known as radionuclides or radiopharmaceuticals for the treatment of certain types of cancer such as thyroid, bone, and prostate cancer. These drugs are made up of a radioactive substance. They are mainly given by mouth or put into a vein, and then travel throughout the body. Radiation injury drugs are used in the detection of cancer, during bone metastasis when cancer spreads to the bone. These drugs are used to diagnose other non-cancer health problems.
Radiation Injury Drugs Market Dynamics
Rising prevalence of cancer patients globally, as well as their preference for radiation therapy, are driving the radiation injury drugs market. According to the International Agency for Research on Cancer, 19.3 million cancer cases and 10 million cancer deaths are expected to occur globally in 2020.
Expansion of the radiation injury medicine market is anticipated to be fueled by an increase in cancer patients. Increased reimbursement policies for radiation therapy and associated treatment for side effects are expected to fuel the radiation injury drugs market.
The day-to-day components of the RO-APM are controlled by a mix of clinicians, the nursing team, radiation therapists, as well as billing and administration employees at the clinical sharp-end. Participating care providers will get all-inclusive reimbursement (rather than fee-for-service), indicating that workflow efficiency will become a defining credo – and the only way for clinics to succeed financially in the long run.
According to the World Cancer Report, cancer has a high incidence rate over the world, with an estimated 20 million cases by 2030. (WHO, 2008). Every year in India, approximately 0.95 million new cancer cases are discovered, with 0.63 million deaths. Breast cancer is frequent among women, and it is the second highest cause of mortality in women. Despite the fact that the prevalence of breast cancer in developing nations is relatively low, industrialized countries diagnose nearly half of all instances of breast cancer.
According to a study conducted between 1975 and 1990, Asia and Africa registered a faster increase in the annual incidence rate of breast cancer than North America and Europe. Increasing number of awareness campaigns about the benefits of radiotherapy and technological developments in radiotherapy devices led to rising use of radiotherapy devices and treatments. The ESTRO Cancer Foundation and ESTRO launched the Marie Curie Legacy Campaign, a global movement, to raise awareness about the benefits of radiotherapy and improve radiotherapy delivery throughout Europe and beyond.
During the projected period, development prospects in emerging markets and rising demand for cancer treatment are expected to present multiple opportunities for market expansion. Radiotherapy, known as radiation therapy, is a treatment for cancer patients that involves eliminating cancer cells and shrinking tumors. Radiation such as X-rays, gamma rays, and charged particles are often employed in radiotherapy.
According to the National Cancer Institute, nearly half of all cancer patients receive radiation therapy as part of their treatment. In the future years, emerging economies such as India, China, Brazil, and Russia are expected to demonstrate tremendous development potential.
India and China are home to more than half of the world's population, and these markets have a huge number of end users in the radiation injury drugs market. This is fuelled by the rising cancer rates in these countries. During the projected period, development prospects in emerging markets and increasing demand for cancer treatment are expected to present several opportunities for market expansion.
Radiation Injury Drugs Market Segmental Outlook
By Exposure
On the basis of exposure, the radiation injury drugs market is segregated into internal exposure and external exposure. The external exposure segment is projected to hold a significant market share during the forecast period.
By Route of Administration
On the basis of route of administration, the radiation injury drugs market is segmented into oral and parenteral. The parenteral segment is expected to account for a significant share of the market in the projected timeline.
By Diagnosis
On the basis of diagnosis, the radiation injury drugs market is divided into lymphocytes count, Geiger-Muller counter, and blood test, and dosimeter. The blood test and dosimeter segment is estimated to constitute a significant share of the market during the forecast period.
By Application
On the basis of applications, the radiation injury drugs market is categorized as ambulatory surgery centers (ASCs), hospitals, research institutes, and others (long-term care centers). High purchasing power of hospitals to buy advanced radiation drugs connectivity solutions, decreasing hospital margins, and growing focus on providing high-quality patient care and safety are key factors that are estimated to drive the hospitals segment growth.
Radiation Injury Drugs Market Region Wise Outlook
Based on regions, the global radiation injury drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America is expected to grow at a rapid pace than the market in the rest of the world, owing to the rising number of cancer patients.
As a result, demand for radiotherapy increased in the region, along with healthcare spending. Europe accounts for a significant share of the market, due to growing treatment of radiation injury. For example, cutaneous radiation injury therapy is common in Europe.
Asia Pacific constitutes a significant market share, particularly China, due to growing number of patients and low treatment cost. South Africa is projected to dominate the MEA radiation injury drugs market with a considerable share. The market is growing, due to the frequency of cancer, high mortality rate, and favorable government regulations. Growing geriatric population is driving the Radiation Injury Drugs Market in Latin America. Globally, the geriatric population is rapidly increasing, contributing to an increase in chronic diseases.
Key Benefits for Industry Participants & Stakeholders
- In-Depth Analysis of the global radiation injury drugs market.
- Historical, Current and Projected Market Size in Terms of Value.
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on global radiation injury drugs market performance
Segments
By Exposure
- Internal Exposure
- External Exposure
By Source
- Background Radiation
- Man-Made Radiation
By Diagnosis
- Lymphocytes Count
- Geiger-Muller Counter
- Blood Test and Dosimeter
By Treatment
- Treatment For Radiation Sickness
- Treatment For Internal Contamination
- Others
By Route of Administration
- Oral
- Parenteral
By Application
- Ambulatory Surgery Centers (ASCs)
- Hospitals
- Research Institutes
- Others
By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Key Market Players Profiled in the Report
- Eli Lilly and Company
- Teva Pharmaceutical
- Amgen Inc.
- La Jolla Pharmaceutical Co
- Novartis
- Johnson & Johnson
- Heyl Chemisch-pharmazeutische Fabrik
Competitive Landscape
- Key players in the global radiation injury drugs market are Eli Lilly and Company, Teva Pharmaceutical, Amgen Inc, La Jolla Pharmaceutical Co, Novartis, Johnson & Johnson, Heyl Chemisch-pharmazeutische Fabrik.
- The players are adopting key strategies such as product development, geographical expansion, mergers and acquisition and many other strategies to cater the increasing demand for radiation injury drugs market.
Frequently Asked Questions
Major Manufactures include Eli Lilly and Company, Teva Pharmaceutical, Amgen Inc, La Jolla Pharmaceutical Co, Novartis, Johnson & Johnson, Heyl Chemisch-pharmazeutische Fabrik.
The base year considered for the global radiation injury drugs market report is 2020. The complete analysis period is 2018 to 2028, wherein, 2018 & 2019 are the historic years, and the forecast is provided from 2021 to 2028.
The market is expected to witness sluggish growth with slow increase in terms of demand during 2019-2020 owing to the negative impact of COVID-19 pandemic on the global radiation injury drugs market.
Ambulatory Surgery Centers (ASCs), Hospitals, Research Institutes, and Long-Term Care Centers are expected to expand at a substantial rate during the forecast period in globe.
Rising prevalence of cancer patients globally, as well as their preference for radiation therapy, are driving the radiation injury drugs market. Investments in R&D sector of radiation injury drugs are increasing globally, which is also estimated to drive the market.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
In addition to market size (in USD Million) and Company Market Share (in % for base year 2020), other data such Macro-economic factors, COVID-19 Impact on the global radiation injury drugs market is available in final report.
According to this Growth Market Reports, the market from global radiation injury drugs market is likely to register a CAGR of 3.7% during period 2021-2028, with an anticipated valuation of USD 747.9 million by the end of the 2028.
Additional company profiles can be provided on request.
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Radiation Injury Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Radiation Injury Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Radiation Injury Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Radiation Injury Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Radiation Injury Drugs Market Size & Forecast, 2018-2028
4.5.1 Radiation Injury Drugs Market Size and Y-o-Y Growth
4.5.2 Radiation Injury Drugs Market Absolute $ Opportunity
4.6 Global Radiation Injury Drugs Market: Impact of Key Regulations
4.7 Global Radiation Injury Drugs Market: Pipeline Analysis
Chapter 5 Global Radiation Injury Drugs Market Analysis and Forecast By Exposure
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Exposure
5.1.2 Basis Point Share (BPS) Analysis By Exposure
5.1.3 Absolute $ Opportunity Assessment By Exposure
5.2 Radiation Injury Drugs Market Size Forecast By Exposure
5.2.1 Internal Exposure
5.2.2 External Exposure
5.3 Market Attractiveness Analysis By Exposure
Chapter 6 Global Radiation Injury Drugs Market Analysis and Forecast By Source
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Source
6.1.2 Basis Point Share (BPS) Analysis By Source
6.1.3 Absolute $ Opportunity Assessment By Source
6.2 Radiation Injury Drugs Market Size Forecast By Source
6.2.1 Background Radiation
6.2.2 Man-made Radiation
6.3 Market Attractiveness Analysis By Source
Chapter 7 Global Radiation Injury Drugs Market Analysis and Forecast By Diagnosis
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Diagnosis
7.1.2 Basis Point Share (BPS) Analysis By Diagnosis
7.1.3 Absolute $ Opportunity Assessment By Diagnosis
7.2 Radiation Injury Drugs Market Size Forecast By Diagnosis
7.2.1 Lymphocytes Count
7.2.2 Geiger-Muller Counter
7.2.3 Blood Test And dosimeter
7.3 Market Attractiveness Analysis By Diagnosis
Chapter 8 Global Radiation Injury Drugs Market Analysis and Forecast By Treatment
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By Treatment
8.1.2 Basis Point Share (BPS) Analysis By Treatment
8.1.3 Absolute $ Opportunity Assessment By Treatment
8.2 Radiation Injury Drugs Market Size Forecast By Treatment
8.2.1 Treatment For Radiation Sickness
8.2.2 Treatment For Internal Contamination
8.2.3 Others
8.3 Market Attractiveness Analysis By Treatment
Chapter 9 Global Radiation Injury Drugs Market Analysis and Forecast By Route of Administration
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities By Route of Administration
9.1.2 Basis Point Share (BPS) Analysis By Route of Administration
9.1.3 Absolute $ Opportunity Assessment By Route of Administration
9.2 Radiation Injury Drugs Market Size Forecast By Route of Administration
9.2.1 Oral
9.2.2 Parenteral
9.3 Market Attractiveness Analysis By Route of Administration
Chapter 10 Global Radiation Injury Drugs Market Analysis and Forecast By Applications
10.1 Introduction
10.1.1 Key Market Trends & Growth Opportunities By Applications
10.1.2 Basis Point Share (BPS) Analysis By Applications
10.1.3 Absolute $ Opportunity Assessment By Applications
10.2 Radiation Injury Drugs Market Size Forecast By Applications
10.2.1 Ambulatory Surgery Centers (ASCs)
10.2.2 Hospitals
10.2.3 Research Institutes
10.2.4 Others
10.3 Market Attractiveness Analysis By Application
Chapter 11 Global Radiation Injury Drugs Market Analysis and Forecast by Region
11.1 Introduction
11.1.1 Key Market Trends & Growth Opportunities by Region
11.1.2 Basis Point Share (BPS) Analysis by Region
11.1.3 Absolute $ Opportunity Assessment by Region
11.2 Radiation Injury Drugs Market Size Forecast by Region
11.2.1 North America
11.2.2 Europe
11.2.3 Asia Pacific
11.2.4 Latin America
11.2.5 Middle East & Africa (MEA)
11.3 Market Attractiveness Analysis by Region
Chapter 12 Coronavirus Disease (COVID-19) Impact
12.1 Introduction
12.2 Current & Future Impact Analysis
12.3 Economic Impact Analysis
12.4 Government Policies
12.5 Investment Scenario
Chapter 13 North America Radiation Injury Drugs Analysis and Forecast
13.1 Introduction
13.2 North America Radiation Injury Drugs Market Size Forecast by Country
13.2.1 U.S.
13.2.2 Canada
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 North America Radiation Injury Drugs Market Size Forecast By Exposure
13.6.1 Internal Exposure
13.6.2 External Exposure
13.7 Basis Point Share (BPS) Analysis By Exposure
13.8 Absolute $ Opportunity Assessment By Exposure
13.9 Market Attractiveness Analysis By Exposure
13.10 North America Radiation Injury Drugs Market Size Forecast By Source
13.10.1 Background Radiation
13.10.2 Man-made Radiation
13.11 Basis Point Share (BPS) Analysis By Source
13.12 Absolute $ Opportunity Assessment By Source
13.13 Market Attractiveness Analysis By Source
13.14 North America Radiation Injury Drugs Market Size Forecast By Diagnosis
13.14.1 Lymphocytes Count
13.14.2 Geiger-Muller Counter
13.14.3 Blood Test And dosimeter
13.15 Basis Point Share (BPS) Analysis By Diagnosis
13.16 Absolute $ Opportunity Assessment By Diagnosis
13.17 Market Attractiveness Analysis By Diagnosis
13.18 North America Radiation Injury Drugs Market Size Forecast By Treatment
13.18.1 Treatment For Radiation Sickness
13.18.2 Treatment For Internal Contamination
13.18.3 Others
13.19 Basis Point Share (BPS) Analysis By Treatment
13.20 Absolute $ Opportunity Assessment By Treatment
13.21 Market Attractiveness Analysis By Treatment
13.22 North America Radiation Injury Drugs Market Size Forecast By Route of Administration
13.22.1 Oral
13.22.2 Parenteral
13.23 Basis Point Share (BPS) Analysis By Route of Administration
13.24 Absolute $ Opportunity Assessment By Route of Administration
13.25 Market Attractiveness Analysis By Route of Administration
13.26 North America Radiation Injury Drugs Market Size Forecast By Applications
13.26.1 Ambulatory Surgery Centers (ASCs)
13.26.2 Hospitals
13.26.3 Research Institutes
13.26.4 Others
13.27 Basis Point Share (BPS) Analysis By Applications
13.28 Absolute $ Opportunity Assessment By Applications
13.29 Market Attractiveness Analysis By Applications
Chapter 14 Europe Radiation Injury Drugs Analysis and Forecast
14.1 Introduction
14.2 Europe Radiation Injury Drugs Market Size Forecast by Country
14.2.1 Germany
14.2.2 France
14.2.3 Italy
14.2.4 U.K.
14.2.5 Spain
14.2.6 Russia
14.2.7 Rest of Europe
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Europe Radiation Injury Drugs Market Size Forecast By Exposure
14.6.1 Internal Exposure
14.6.2 External Exposure
14.7 Basis Point Share (BPS) Analysis By Exposure
14.8 Absolute $ Opportunity Assessment By Exposure
14.9 Market Attractiveness Analysis By Exposure
14.10 Europe Radiation Injury Drugs Market Size Forecast By Source
14.10.1 Background Radiation
14.10.2 Man-made Radiation
14.11 Basis Point Share (BPS) Analysis By Source
14.12 Absolute $ Opportunity Assessment By Source
14.13 Market Attractiveness Analysis By Source
14.14 Europe Radiation Injury Drugs Market Size Forecast By Diagnosis
14.14.1 Lymphocytes Count
14.14.2 Geiger-Muller Counter
14.14.3 Blood Test And dosimeter
14.15 Basis Point Share (BPS) Analysis By Diagnosis
14.16 Absolute $ Opportunity Assessment By Diagnosis
14.17 Market Attractiveness Analysis By Diagnosis
14.18 Europe Radiation Injury Drugs Market Size Forecast By Treatment
14.18.1 Treatment For Radiation Sickness
14.18.2 Treatment For Internal Contamination
14.18.3 Others
14.19 Basis Point Share (BPS) Analysis By Treatment
14.20 Absolute $ Opportunity Assessment By Treatment
14.21 Market Attractiveness Analysis By Treatment
14.22 Europe Radiation Injury Drugs Market Size Forecast By Route of Administration
14.22.1 Oral
14.22.2 Parenteral
14.23 Basis Point Share (BPS) Analysis By Route of Administration
14.24 Absolute $ Opportunity Assessment By Route of Administration
14.25 Market Attractiveness Analysis By Route of Administration
14.26 Europe Radiation Injury Drugs Market Size Forecast By Applications
14.26.1 Ambulatory Surgery Centers (ASCs)
14.26.2 Hospitals
14.26.3 Research Institutes
14.26.4 Others
14.27 Basis Point Share (BPS) Analysis By Applications
14.28 Absolute $ Opportunity Assessment By Applications
14.29 Market Attractiveness Analysis By Applications
Chapter 15 Asia Pacific Radiation Injury Drugs Analysis and Forecast
15.1 Introduction
15.2 Asia Pacific Radiation Injury Drugs Market Size Forecast by Country
15.2.1 China
15.2.2 Japan
15.2.3 South Korea
15.2.4 India
15.2.5 Australia
15.2.6 South East Asia (SEA)
15.2.7 Rest of Asia Pacific (APAC)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Asia Pacific Radiation Injury Drugs Market Size Forecast By Exposure
15.6.1 Internal Exposure
15.6.2 External Exposure
15.7 Basis Point Share (BPS) Analysis By Exposure
15.8 Absolute $ Opportunity Assessment By Exposure
15.9 Market Attractiveness Analysis By Exposure
15.10 Asia Pacific Radiation Injury Drugs Market Size Forecast By Source
15.10.1 Background Radiation
15.10.2 Man-made Radiation
15.11 Basis Point Share (BPS) Analysis By Source
15.12 Absolute $ Opportunity Assessment By Source
15.13 Market Attractiveness Analysis By Source
15.14 Asia Pacific Radiation Injury Drugs Market Size Forecast By Diagnosis
15.14.1 Lymphocytes Count
15.14.2 Geiger-Muller Counter
15.14.3 Blood Test And dosimeter
15.15 Basis Point Share (BPS) Analysis By Diagnosis
15.16 Absolute $ Opportunity Assessment By Diagnosis
15.17 Market Attractiveness Analysis By Diagnosis
15.18 Asia Pacific Radiation Injury Drugs Market Size Forecast By Treatment
15.18.1 Treatment For Radiation Sickness
15.18.2 Treatment For Internal Contamination
15.18.3 Others
15.19 Basis Point Share (BPS) Analysis By Treatment
15.20 Absolute $ Opportunity Assessment By Treatment
15.21 Market Attractiveness Analysis By Treatment
15.22 Asia Pacific Radiation Injury Drugs Market Size Forecast By Route of Administration
15.22.1 Oral
15.22.2 Parenteral
15.23 Basis Point Share (BPS) Analysis By Route of Administration
15.24 Absolute $ Opportunity Assessment By Route of Administration
15.25 Market Attractiveness Analysis By Route of Administration
15.26 Asia Pacific Radiation Injury Drugs Market Size Forecast By Applications
15.26.1 Ambulatory Surgery Centers (ASCs)
15.26.2 Hospitals
15.26.3 Research Institutes
15.26.4 Others
15.27 Basis Point Share (BPS) Analysis By Applications
15.28 Absolute $ Opportunity Assessment By Applications
15.29 Market Attractiveness Analysis By Applications
Chapter 16 Latin America Radiation Injury Drugs Analysis and Forecast
16.1 Introduction
16.2 Latin America Radiation Injury Drugs Market Size Forecast by Country
16.2.1 Brazil
16.2.2 Mexico
16.2.3 Rest of Latin America (LATAM)
16.3 Basis Point Share (BPS) Analysis by Country
16.4 Absolute $ Opportunity Assessment by Country
16.5 Market Attractiveness Analysis by Country
16.6 Latin America Radiation Injury Drugs Market Size Forecast By Exposure
16.6.1 Internal Exposure
16.6.2 External Exposure
16.7 Basis Point Share (BPS) Analysis By Exposure
16.8 Absolute $ Opportunity Assessment By Exposure
16.9 Market Attractiveness Analysis By Exposure
16.10 Latin America Radiation Injury Drugs Market Size Forecast By Source
16.10.1 Background Radiation
16.10.2 Man-made Radiation
16.11 Basis Point Share (BPS) Analysis By Source
16.12 Absolute $ Opportunity Assessment By Source
16.13 Market Attractiveness Analysis By Source
16.14 Latin America Radiation Injury Drugs Market Size Forecast By Diagnosis
16.14.1 Lymphocytes Count
16.14.2 Geiger-Muller Counter
16.14.3 Blood Test And dosimeter
16.15 Basis Point Share (BPS) Analysis By Diagnosis
16.16 Absolute $ Opportunity Assessment By Diagnosis
16.17 Market Attractiveness Analysis By Diagnosis
16.18 Latin America Radiation Injury Drugs Market Size Forecast By Treatment
16.18.1 Treatment For Radiation Sickness
16.18.2 Treatment For Internal Contamination
16.18.3 Others
16.19 Basis Point Share (BPS) Analysis By Treatment
16.20 Absolute $ Opportunity Assessment By Treatment
16.21 Market Attractiveness Analysis By Treatment
16.22 Latin America Radiation Injury Drugs Market Size Forecast By Route of Administration
16.22.1 Oral
16.22.2 Parenteral
16.23 Basis Point Share (BPS) Analysis By Route of Administration
16.24 Absolute $ Opportunity Assessment By Route of Administration
16.25 Market Attractiveness Analysis By Route of Administration
16.26 Latin America Radiation Injury Drugs Market Size Forecast By Applications
16.26.1 Ambulatory Surgery Centers (ASCs)
16.26.2 Hospitals
16.26.3 Research Institutes
16.26.4 Others
16.27 Basis Point Share (BPS) Analysis By Applications
16.28 Absolute $ Opportunity Assessment By Applications
16.29 Market Attractiveness Analysis By Applications
Chapter 17 Middle East & Africa (MEA) Radiation Injury Drugs Analysis and Forecast
17.1 Introduction
17.2 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast by Country
17.2.1 Saudi Arabia
17.2.2 South Africa
17.2.3 UAE
17.2.4 Rest of Middle East & Africa (MEA)
17.3 Basis Point Share (BPS) Analysis by Country
17.4 Absolute $ Opportunity Assessment by Country
17.5 Market Attractiveness Analysis by Country
17.6 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Exposure
17.6.1 Internal Exposure
17.6.2 External Exposure
17.7 Basis Point Share (BPS) Analysis By Exposure
17.8 Absolute $ Opportunity Assessment By Exposure
17.9 Market Attractiveness Analysis By Exposure
17.10 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Source
17.10.1 Background Radiation
17.10.2 Man-made Radiation
17.11 Basis Point Share (BPS) Analysis By Source
17.12 Absolute $ Opportunity Assessment By Source
17.13 Market Attractiveness Analysis By Source
17.14 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Diagnosis
17.14.1 Lymphocytes Count
17.14.2 Geiger-Muller Counter
17.14.3 Blood Test And dosimeter
17.15 Basis Point Share (BPS) Analysis By Diagnosis
17.16 Absolute $ Opportunity Assessment By Diagnosis
17.17 Market Attractiveness Analysis By Diagnosis
17.18 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Treatment
17.18.1 Treatment For Radiation Sickness
17.18.2 Treatment For Internal Contamination
17.18.3 Others
17.19 Basis Point Share (BPS) Analysis By Treatment
17.20 Absolute $ Opportunity Assessment By Treatment
17.21 Market Attractiveness Analysis By Treatment
17.22 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Route of Administration
17.22.1 Oral
17.22.2 Parenteral
17.23 Basis Point Share (BPS) Analysis By Route of Administration
17.24 Absolute $ Opportunity Assessment By Route of Administration
17.25 Market Attractiveness Analysis By Route of Administration
17.26 Middle East & Africa (MEA) Radiation Injury Drugs Market Size Forecast By Applications
17.26.1 Ambulatory Surgery Centers (ASCs)
17.26.2 Hospitals
17.26.3 Research Institutes
17.26.4 Others
17.27 Basis Point Share (BPS) Analysis By Applications
17.28 Absolute $ Opportunity Assessment By Applications
17.29 Market Attractiveness Analysis By Applications
Chapter 18 Competition Landscape
18.1 Radiation Injury Drugs Market: Competitive Dashboard
18.2 Global Radiation Injury Drugs Market: Market Share Analysis, 2020
18.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
18.3.1 Eli Lilly and Company
18.3.2 Teva Pharmaceutical
18.3.3 Amgen Inc
18.3.4 La Jolla Pharmaceutical Co
18.3.5 Novartis
18.3.6 Johnson & Johnson
18.3.7 Heyl Chemisch-pharmazeutische Fabrik
Methodology
Related Reports
Some other reports from this category!
Our Clients
